

Remarks/Arguments

It is irrelevant to enablement whether combinations with CDK inhibitors other than flavopiridol also show synergistic effects when combined with imatinib because, with the exception of claim 22, the present claims do not require synergy. The present specification discloses that bcr-abl positive, imatinib-resistant leukemia can be treated with a combination of a CDK inhibitor and imatinib. All that is needed to carry out the claimed invention is knowledge of whether a pharmaceutical agent inhibits CDK and a diagnosis that the leukemia is bcr-abl positive and imatinib-resistant. Both of these can be determined using routine experimentation by one of ordinary skill in the art. Therefore, the enablement requirement is satisfied.

With respect to claim 22, the present specification provides data which teaches the skilled artisan to use a synergistic amount of imatinib and flavopiridol. Thus, claim 22 is also enabled.

Entry of this submission is respectfully requested.

Novartis Pharmaceuticals Corporation  
One Health Plaza, Bldg. 101  
East Hanover, NJ 07936  
(862) 778-7824

Date: 6/3/10

Respectfully submitted,



George Dohmann  
Attorney for Applicant  
Reg. No. 33,593